Free Trial

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$141.96
+0.97 (+0.69%)
(As of 06/21/2024 ET)

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$145.67
2.61% Upside
High Forecast$163.00
Average Forecast$145.67
Low Forecast$115.00
TypeCurrent Forecast
6/24/23 to 6/23/24
1 Month Ago
5/25/23 to 5/24/24
3 Months Ago
3/26/23 to 3/25/24
1 Year Ago
6/24/22 to 6/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$145.67$133.60$126.25$36.25
Forecasted Upside2.61% Upside22.63% Upside18.24% Upside12.21% Upside
Get Novo Nordisk A/S Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novo Nordisk A/S Stock vs. The Competition

TypeNovo Nordisk A/SMedical CompaniesS&P 500
Consensus Rating Score
2.78
2.70
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside2.61% Upside900.45% Upside10.90% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/17/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00 ➝ $160.00+13.31%
6/10/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$125.00 ➝ $160.00+13.09%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$156.00+17.58%
4/12/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$163.00+29.98%
1/23/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$120.00+13.75%
1/16/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
12/4/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$105.00 ➝ $115.00+14.19%
8/11/2023DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
4/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform
12/12/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$32.50 ➝ $36.25+11.94%
9/29/2022Oddo Bhf
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:56 PM ET.

NVO Forecast - Frequently Asked Questions

What is Novo Nordisk A/S's stock forecast and purchase recommendation?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $145.67, with a high forecast of $163.00 and a low forecast of $115.00. The consensus rating for Novo Nordisk A/S stock is Moderate Buy based on the current 2 hold ratings and 7 buy ratings for NVO. Learn more on NVO's analyst rating history.

Do Wall Street analysts like Novo Nordisk A/S more than its competitors?

Analysts like Novo Nordisk A/S more than other "medical" companies. The consensus rating score for Novo Nordisk A/S is 2.78 while the average consensus rating score for "medical" companies is 2.70. Learn more on how NVO compares to other companies.

Does Novo Nordisk A/S's stock price have much upside?

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 17.01% based on their 12-month stock forecasts.

What analysts cover Novo Nordisk A/S?

Novo Nordisk A/S has been rated by research analysts at Argus, BMO Capital Markets, Cantor Fitzgerald, and The Goldman Sachs Group in the past 90 days.


Stock Forecasts and Research Tools

This page (NYSE:NVO) was last updated on 6/23/2024 by MarketBeat.com Staff

From Our Partners